Vasculitis trials

Trials open to recruitment

ACQUIVAS

Antineutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) has been transformed from a largely fatal condition to a chronic relapsing disorder following the introduction of cyclophosphamide and glucocorticoids 40 years ago. Despite…

APRIL

Rheumatoid arthritis is a multi-system, autoimmune disease characterised by progressive inflammation and destruction of synovial joints and extra-articular structures. In recent decades, the natural history of rheumatoid arthritis (RA) has…

BIOVAS

Glucocorticoids remain the standard therapy for remission induction in non-ANCA associated vasculitis (NAAV) and are used with or without immunosuppressive agents depending on the syndrome and severity. Glucocorticoids at high doses control…

COMBIVAS

The principle of using multiple agents to target different disease mechanisms is gaining traction in many autoimmune disease settings. This trial will study the combination of rituximab and belimumab in anti-neutrophil cytoplasmic antibody (ANCA…